Recent Finacing
Recent Raise
Antios is a clinical-stage biopharmaceutical company developing ATI-2173, a liver-targeted oral ASPIN for once-daily treatment of chronic hepatitis B, currently in Phase 2b trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Antios Therapeutics.
